• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Vermillion forms new strategic and medical advisory board

Vermillion forms new strategic and medical advisory board

November 20, 2014
CenterWatch Staff

Vermillion, a bio-analytical solutions company focused on gynecologic disease, recently outlined its expanded strategy for driving improvements in the personalized management of gynecologic health and becoming a leading diagnostic innovator in gynecologic informatics. In support of this mission, the company has named three charter members of its strategic and medical advisory board.

To date, Vermillion has focused on one "leg" of the clinical decision tree that begins with hundreds of thousands of women seeking treatment for non-specific gynecologic symptoms including pain, infertility or irregular menstrual cycles. Vermillion hopes to aid clinicians in the triage of these women into effective and cost efficient treatment pathways that address both malignant and benign gynecologic disease.

"Just as Vermillion succeeded in identifying the OVA1 algorithm which pre-operatively predicts ovarian cancer status, similar tools can be used to predict and diagnose the other conditions found in what we call the 'confusion matrix'," said Dr. Judith Wolf, Vermillion's chief medical officer. “Early detection and diagnosis translates into quality of care, and aids in cost-effective, targeted, management of patients.”

"We now view informatics and care pathways, not simply biomarkers, as part of the formula for achieving our goal of optimizing care for women who are facing serious malignant and benign gynecologic conditions," said Dr. Donald Munroe, Vermillion's chief scientific officer. “To that end, we plan to expand our predictive tools to include other modalities, clinical risk factors, and patient informatics in our calculus. These proprietary predictive methods will use newly discovered correlations and algorithms … to better diagnose and therefore effectively treat women.”

The Strategic & Medical Advisory Board (SMAB) will be comprised of experts in a diverse range of subjects including gynecologic oncology, clinical chemistry, data science, reimbursement and medical policy, and patient advocacy. The SMAB will be co-led by Vermillion's Wolf and Munroe.

Its charter members are:

  • Dr. Daniel Chan, professor of pathology, oncology, urology and radiology, director of clinical chemistry division, department of pathology, and the director, Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine.
  • Dr. Robert E. Bristow holds the Philip J. DiSaia chair in gynecologic oncology and is director of gynecologic oncology and vice-chair for clinical affairs and quality improvement at the University of California, Irvine.
  • Calaneet Balas, CEO of the Ovarian Cancer National Alliance (OCNA), has more than 15 years experience in development and strategic planning. She previously worked at the Arthritis Foundation as the chief strategy officer of the Mid-Atlantic Region and as president/CEO of the Arthritis Foundation's Metro DC Chapter.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing